Eupraxia Pharmaceuticals Common Stock Market Outlook
| EPRX Stock | 8.18 0.13 1.61% |
Slightly above 62% of all Eupraxia Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Eupraxia Pharmaceuticals Common suggests that some traders are interested. Eupraxia Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Eupraxia Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 62
Interested
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Eupraxia Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Eupraxia Pharmaceuticals Common.
News SentimentBullish | Hype SentimentBullish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Eupraxia Pharmaceuticals Common is 'Buy'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Eupraxia Pharmaceuticals Common given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Eupraxia Pharmaceuticals Common, the advice is generated through an automated system that utilizes algorithms and statistical models.
Execute Eupraxia Pharmaceuticals Advice
The Eupraxia recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Eupraxia Pharmaceuticals Common. Macroaxis does not own or have any residual interests in Eupraxia Pharmaceuticals Common or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Eupraxia Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Buy
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Eupraxia Pharmaceuticals Common has a Risk Adjusted Performance of 0.1004, Jensen Alpha of 0.4451, Total Risk Alpha of 0.0568, Sortino Ratio of 0.152 and Treynor Ratio of 0.9118We provide trade advice to complement the prevailing expert consensus on Eupraxia Pharmaceuticals. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. To make sure Eupraxia Pharmaceuticals is not overpriced, please confirm all Eupraxia Pharmaceuticals fundamentals, including its number of shares shorted, cash flow from operations, as well as the relationship between the Cash Flow From Operations and market capitalization . Given that Eupraxia Pharmaceuticals has a shares owned by institutions of 32.00 %, we urge you to verify Eupraxia Pharmaceuticals Common market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your prevailing risk tolerance and investing horizon.
Eupraxia Pharmaceuticals Trading Alerts and Improvement Suggestions
| Eupraxia Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Eupraxia Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (25.74 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eupraxia Pharmaceuticals generates negative cash flow from operations | |
| Eupraxia Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| About 15.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Technical Pivots with Risk Controls - Stock Traders Daily |
Eupraxia Pharmaceuticals Returns Distribution Density
The distribution of Eupraxia Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Eupraxia Pharmaceuticals' future price movements. The chart of the probability distribution of Eupraxia Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Eupraxia Pharmaceuticals Common price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Eupraxia Pharmaceuticals returns is essential to provide solid investment analysis for Eupraxia Pharmaceuticals.
| Mean Return | 0.50 | Value At Risk | -4.46 | Potential Upside | 6.71 | Standard Deviation | 4.13 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Eupraxia Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Eupraxia Pharmaceuticals Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 16.4M | 5.7M | 1.1M | 13.8M | 15.8M | 16.6M | |
| Free Cash Flow | (11.9M) | (14.6M) | (20.8M) | (30.1M) | (27.1M) | (25.7M) | |
| Depreciation | 88.2K | 147.9K | 155.5K | 171.7K | 197.5K | 150.3K | |
| Other Non Cash Items | 6.7M | 1.5M | 1.3M | (880.5K) | (792.4K) | (752.8K) | |
| Capital Expenditures | 341.3K | 235.6K | 73.4K | 104.2K | 93.8K | 122.0K | |
| Net Income | (18.2M) | (19.0M) | (29.0M) | (25.7M) | (23.2M) | (24.3M) | |
| End Period Cash Flow | 16.5M | 18.3M | 19.3M | 33.1M | 38.1M | 40.0M | |
| Investments | (14.4M) | 9.8M | (73.4K) | (75.2K) | (86.4K) | (90.8K) |
Eupraxia Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Eupraxia Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Eupraxia Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Eupraxia stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.45 | |
β | Beta against Dow Jones | 0.54 | |
σ | Overall volatility | 4.23 | |
Ir | Information ratio | 0.1 |
Eupraxia Pharmaceuticals Volatility Alert
Eupraxia Pharmaceuticals Common currently demonstrates below-average downside deviation. It has Information Ratio of 0.1 and Jensen Alpha of 0.45. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Eupraxia Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Eupraxia Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Eupraxia Pharmaceuticals Fundamentals Vs Peers
Comparing Eupraxia Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Eupraxia Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Eupraxia Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Eupraxia Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Eupraxia Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Eupraxia Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Eupraxia Pharmaceuticals to competition |
| Fundamentals | Eupraxia Pharmaceuticals | Peer Average |
| Return On Equity | -0.61 | -0.31 |
| Return On Asset | -0.36 | -0.14 |
| Current Valuation | 355.45 M | 16.62 B |
| Shares Outstanding | 50.65 M | 571.82 M |
| Shares Owned By Insiders | 15.02 % | 10.09 % |
| Shares Owned By Institutions | 32.00 % | 39.21 % |
| Number Of Shares Shorted | 1.66 M | 4.71 M |
| Price To Book | 7.07 X | 9.51 X |
| EBITDA | (35.91 M) | 3.9 B |
| Net Income | (25.74 M) | 570.98 M |
| Total Debt | 71.86 K | 5.32 B |
| Book Value Per Share | 1.15 X | 1.93 K |
| Cash Flow From Operations | (29.99 M) | 971.22 M |
| Short Ratio | 9.07 X | 4.00 X |
| Earnings Per Share | (0.88) X | 3.12 X |
| Target Price | 14.4 | |
| Number Of Employees | 33 | 18.84 K |
| Beta | 1.5 | -0.15 |
| Market Capitalization | 419.12 M | 19.03 B |
| Total Asset | 34.94 M | 29.47 B |
| Retained Earnings | (131 M) | 9.33 B |
| Working Capital | 31.33 M | 1.48 B |
| Net Asset | 34.94 M |
Eupraxia Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Eupraxia . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
Eupraxia Pharmaceuticals Analyst Ratings
Eupraxia Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Eupraxia Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Eupraxia Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Eupraxia Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Eupraxia Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Eupraxia Pharmaceuticals Common? Buying financial instruments such as Eupraxia Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Eupraxia Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Recycling Thematic Idea Now
Recycling
West management companies as well as entities specializing in pollution control and recycling. The Recycling theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Recycling Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Eupraxia Stock Analysis
When running Eupraxia Pharmaceuticals' price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.